P10 | Jotup

Enhanced Capital Group Named to 13th Annual ImpactAssets 50 List

Retrieved on:

Wednesday, April 3, 2024

DALLAS, April 03, 2024 (GLOBE NEWSWIRE) -- P10, Inc. (NYSE: PX), a leading private markets solutions provider, today announced that its subsidiary Enhanced Capital Group LLC was named to the ImpactAssets 50™️ (IA 50) 2024 , a free publicly available, searchable database of global impact investment fund managers globally.

Key Points:

DALLAS, April 03, 2024 (GLOBE NEWSWIRE) -- P10, Inc. (NYSE: PX), a leading private markets solutions provider, today announced that its subsidiary Enhanced Capital Group LLC was named to the ImpactAssets 50™️ (IA 50) 2024 , a free publicly available, searchable database of global impact investment fund managers globally.
“P10 is proud of this recognition, and can speak firsthand to Enhanced Capital’s commitment to providing financing solutions to lower middle market borrowers that are seeking non-dilutive capital,” said Luke Sarsfield, P10 Chief Executive Officer.
The IA 50 received a record number of 343 applicants this year with a total of 155 firms selected, demonstrating the growing interest in and demand for the impact investment industry.
“As a private lender since 1999, Enhanced focuses on the lower middle market to provide market rate financing solutions to projects and businesses that meet our underwriting standards but lack access to traditional sources of capital,” said Michael Korengold, Enhanced Capital Chief Executive Officer.

Palatin Announces Results of PL9643 MELODY-1 Pivotal Phase 3 Clinical Trial in Patients with Dry Eye Disease (DED)

Retrieved on:

Wednesday, February 28, 2024

P10, Pain

ET Today

Key Points:

ET Today
CRANBURY, N.J., Feb. 28, 2024 /PRNewswire/ -- Palatin Technologies, Inc. (NYSE American: PTN), a biopharmaceutical company developing first-in-class medicines based on molecules that modulate the activity of the melanocortin receptor system, today announced results for its PL9643 MELODY-1 pivotal Phase 3 clinical trial evaluating the safety and efficacy of PL9643 versus vehicle in the treatment of dry eye disease (DED).
"We are pleased that PL9643 treatment demonstrated excellent safety and tolerability data, including superior efficacy results compared to vehicle across multiple sign endpoints."
The study design was based on positive Phase 2 results of PL9643 for the treatment of DED, and an end-of-Phase 2 meeting with the FDA on key elements of the pivotal Phase 3 clinical program.
Palatin will host a conference call and audio webcast on February 28, 2024, at 8:30 a.m. Eastern Time to discuss the PL9643 Phase 3 clinical study results in greater detail.

P10 Announces Chief Operating Officer William Souder to Retire

Retrieved on:

Friday, February 9, 2024

P10, PX, RCP

DALLAS, Feb. 09, 2024 (GLOBE NEWSWIRE) -- P10, Inc. (NYSE: PX), a leading private markets solutions provider, today announced that William “Fritz” Souder, the Chief Operating Officer of P10, Inc., will be retiring from the Company in May of 2024.

Key Points:

DALLAS, Feb. 09, 2024 (GLOBE NEWSWIRE) -- P10, Inc. (NYSE: PX), a leading private markets solutions provider, today announced that William “Fritz” Souder, the Chief Operating Officer of P10, Inc., will be retiring from the Company in May of 2024.
Prior to Mr. Souder’s departure the company expects to announce a reallocation of his responsibilities.
“Fritz has played an important role in establishing and growing P10 into the world-class alternative asset management firm it is today,” said Luke Sarsfield, Chief Executive Officer.
The firm is incredibly grateful for his years of service and wishes him all of the best in his next chapter.

P10 Schedules Fourth Quarter and Full Year 2023 Earnings Release for Thursday, February 29, 2024

Retrieved on:

Wednesday, February 7, 2024

Telephone, Webcast, PIN, P10, PX

DALLAS, Feb. 07, 2024 (GLOBE NEWSWIRE) -- P10, Inc. (NYSE: PX), a leading private markets solutions provider, today announced it will release its fourth quarter and full year 2023 results on Thursday, February 29, 2024, after U.S. markets close.

Key Points:

DALLAS, Feb. 07, 2024 (GLOBE NEWSWIRE) -- P10, Inc. (NYSE: PX), a leading private markets solutions provider, today announced it will release its fourth quarter and full year 2023 results on Thursday, February 29, 2024, after U.S. markets close.
The company will also host a conference call at 5:00 p.m. Eastern Time on Thursday, February 29, 2024.
All participants joining by telephone should register here for personal dial-in and PIN numbers.
For those unable to participate in the live call, a replay will be made available on P10’s investor relations page at ir.p10alts.com .

RCP Advisors Announces Promotions

Retrieved on:

Tuesday, January 30, 2024

Administration, RCP Advisors, P10, Neuberger Berman, Communication, Research, PX, RCP

CHICAGO, Jan. 30, 2024 (GLOBE NEWSWIRE) -- Following a successful year in 2023, RCP Advisors (“RCP”) is pleased to announce the promotion of Patrick dePenaloza to Principal, alongside several additional promotions across the firm.

Key Points:

CHICAGO, Jan. 30, 2024 (GLOBE NEWSWIRE) -- Following a successful year in 2023, RCP Advisors (“RCP”) is pleased to announce the promotion of Patrick dePenaloza to Principal, alongside several additional promotions across the firm.
Patrick joined RCP’s business development team in 2016 following his earlier relevant experience at Neuberger Berman.
“We are thrilled to announce these well-deserved promotions.
Each of these team members has demonstrated exceptional commitment and talent, and their contributions have been instrumental in RCP’s success,” said Jon Madorsky, Managing Partner at RCP Advisors.

Ipsen confirms U.S. FDA grants priority review for New Drug Application for elafibranor for the treatment of rare cholestatic liver disease, PBC

Retrieved on:

Thursday, December 7, 2023

An oral, once-daily dual peroxisome activated receptor alpha/delta (PPAR α,δ) agonist, investigational elafibranor could potentially be the first novel second-line treatment for the rare, cholestatic liver disease, PBC, in nearly a decade.

Key Points:

An oral, once-daily dual peroxisome activated receptor alpha/delta (PPAR α,δ) agonist, investigational elafibranor could potentially be the first novel second-line treatment for the rare, cholestatic liver disease, PBC, in nearly a decade.
The trial enrolled 161 patients who were randomized 2:1 to receive either elafibranor 80mg once daily or placebo.
ELATIVE also investigated the effect of treatment with elafibranor on pruritus (severe itch), a significant symptom burden amongst people living with PBC.
Findings from the secondary endpoint using the PBC Worst Itch NRS score, showed a reduction in pruritis for elafibranor, which was not statistically significant.

Kayne Anderson Private Credit Announces Strategic Minority Investment From Bonaccord Capital Partners

Retrieved on:

Monday, November 13, 2023

PX, NYSE, Kirkland & Ellis, P10, Growth, KAPC

CHICAGO, Nov. 13, 2023 (GLOBE NEWSWIRE) -- Kayne Anderson Private Credit (“KAPC” or the "Firm"), a middle-market private credit platform with $6 billion of assets under management, is pleased to announce that Bonaccord Capital Partners (“Bonaccord” or “BCP”) has made a passive minority investment in the Firm.

Key Points:

CHICAGO, Nov. 13, 2023 (GLOBE NEWSWIRE) -- Kayne Anderson Private Credit (“KAPC” or the "Firm"), a middle-market private credit platform with $6 billion of assets under management, is pleased to announce that Bonaccord Capital Partners (“Bonaccord” or “BCP”) has made a passive minority investment in the Firm.
Ken Leonard, Co-Head of Kayne Anderson Private Credit commented, “Today’s announcement represents an exciting step in Kayne Anderson Private Credit’s evolution, and we are very pleased that Bonaccord is a minority partner in our business.”
“Bonaccord’s value creation expertise will be a critical element in our strategic toolkit as we focus on continuing to build our platform of private credit offerings that serve our limited partners with reliable capital solutions,” said Doug Goodwillie, Co-Head of Kayne Anderson Private Credit.
“Kayne Anderson Private Credit has built a first-class private credit platform led by an exceptional management and investment team that has consistently generated stable, strong returns on behalf of its investors,” said Ajay Chitkara, Managing Partner at Bonaccord Capital Partners.
“We are excited to be Kayne Anderson Private Credit’s partner of choice and look forward to supporting the Firm’s ongoing success.”
Moelis & Company LLC served as financial adviser to Kayne Anderson Private Credit.

P10 Reports Third Quarter 2023 Results

Retrieved on:

Thursday, November 9, 2023

EBITDA, Growth, P10, PX, NYSE, GAAP, EPS, ANI

DALLAS, Nov. 09, 2023 (GLOBE NEWSWIRE) -- P10, Inc. (NYSE: PX), a leading private markets solutions provider, today reported financial results for the third quarter ended September 30, 2023.

Key Points:

DALLAS, Nov. 09, 2023 (GLOBE NEWSWIRE) -- P10, Inc. (NYSE: PX), a leading private markets solutions provider, today reported financial results for the third quarter ended September 30, 2023.
Third Quarter 2023 Financial Highlights:
Fee Paying Assets Under Management: $22.7 billion, a 20% increase year over year.
As announced on October 23, 2023, Luke Sarsfield has stepped into the role of chief executive officer and is now a member of the board of directors.
He joins P10 at the perfect time as we execute on our next phase of organic and inorganic growth.”
Luke Sarsfield, P10 Chief Executive Officer said, “Our third quarter performance demonstrates the strong fundamentals that will drive future P10 success.

P10 Schedules Third Quarter 2023 Earnings Release for Thursday, November 9, 2023

Retrieved on:

Tuesday, October 24, 2023

Telephone, P10, NYSE, Webcast, PIN, PX

DALLAS, Oct. 24, 2023 (GLOBE NEWSWIRE) -- P10, Inc. (NYSE: PX), a leading private markets solutions provider, today announced it will release its third quarter 2023 results on Thursday, November 9, 2023, after U.S. markets close.

Key Points:

DALLAS, Oct. 24, 2023 (GLOBE NEWSWIRE) -- P10, Inc. (NYSE: PX), a leading private markets solutions provider, today announced it will release its third quarter 2023 results on Thursday, November 9, 2023, after U.S. markets close.
The company will also host a conference call at 5:00 p.m. Eastern Time on Thursday, November 9, 2023.
All participants joining by telephone should register here for personal dial-in and PIN numbers.
For those unable to participate in the live call, a replay will be made available on P10’s investor relations page at ir.p10alts.com .

P10 Appoints Luke Sarsfield as Chief Executive Officer

Retrieved on:

Monday, October 23, 2023

Goldman Sachs, IPO, NYSE, Entrepreneurship, P10, PX, Record, Management

DALLAS, Oct. 23, 2023 (GLOBE NEWSWIRE) -- P10, Inc. (NYSE: PX) (“P10” or the “Company”), a leading private markets solutions provider, today announced the appointment of Luke Sarsfield as the Company’s new Chief Executive Officer, effective immediately. Mr. Sarsfield was also appointed a member of the P10 Board of Directors. P10’s Co-Founders Robert Alpert and Clark Webb, will continue as members of the P10 Board and have been elected Executive Chairman and Executive Vice Chairman, respectively. In his new role, Mr. Alpert will support Mr. Sarsfield in corporate matters. Mr. Webb will direct his attention toward strategic opportunities and assist Mr. Sarsfield in potential corporate transactions.

Key Points:

DALLAS, Oct. 23, 2023 (GLOBE NEWSWIRE) -- P10, Inc. (NYSE: PX) (“P10” or the “Company”), a leading private markets solutions provider, today announced the appointment of Luke Sarsfield as the Company’s new Chief Executive Officer, effective immediately.
Mr. Sarsfield was also appointed a member of the P10 Board of Directors.
P10’s Co-Founders Robert Alpert and Clark Webb, will continue as members of the P10 Board and have been elected Executive Chairman and Executive Vice Chairman, respectively.
Mr. Sarsfield is the former Global Co-Head of Goldman Sachs Asset Management, which managed approximately $2.5 trillion in assets under his leadership.